Investor Area
Klas Therapeutics Ltd is currently seeking investment to help us achieve our mission to disrupt melanoma treatment with our groundbreaking technology that is cost-effective, reduces tumour size and results in minimal scarring or side effects.
KLAS Therapeutics is actively seeking investors who want to make a real difference in the lives of Melanoma sufferers and to become a part of a dynamic team that seeks to push the boundaries of current medical therapies.
Our award-winning spin-out has already achieved anumber of significant milestones, including receiving approximately £1 million in grant funding to date and with your support and investment, we can accelerate our growth to make a positive impact on global heath and improve quality of life for cancer patients.
Get in touch with our team
Contact Klas Therapeutics to learn more about our current investment opportunities and plans for our business.
Klas Therapeutics Highlights
Our patented technology allows PDT to target the melanoma cells with pre-clinical studies showing 500% tumour size reduction compared to PDT alone and eradication of nearly 100% of melanoma cells.
Multi award-winning spin-out consistently recognised for our dedication and innovation having received numerous awards including the prestigious Women TechEU award, Seal of Excellence for EIC and INVENT 2020 Winner.
Our expert team has been and continues to be supported by multiple leading organisations including Ulster University and Innovate UK to help us achieve our mission and work to transform the landscape of melanoma treatment.
To date, Klas Therapeutics has received approximately £1 million in grant funding which has enabled the company to spin-out and make significant progress on our research and stakeholder engagement efforts.